Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2021-06-10 Regulatory Filings
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
US Patent Office Grants Foundational Pharmacogenomic Patent 2 pages 166.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX Market Announcement about the granting of a US patent to Genetic Technologies Limited. It discusses the patent details, its significance, and future product plans. There is no financial data, no mention of financial results, no regulatory certifications, or meeting materials. The document is a corporate announcement about intellectual property, not a financial report or regulatory filing. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under Regulatory Filings (RNS) as a general corporate announcement that does not fit other specific categories.
2021-06-10 English
GTG COVID-19 Risk Test launched in USA 2 pages 152.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX Market Announcement about the launch of a COVID-19 Risk Test in the USA by Genetic Technologies Limited. It provides details about the product launch, regulatory approvals, pricing, and licensing agreements. There are no financial statements, quarterly or annual results, or detailed financial data. The document is a corporate announcement about a product launch and licensing arrangement, not a financial report or regulatory filing. It is also relatively short (3906 characters) and does not indicate it is a report publication announcement or certification. Therefore, the most appropriate classification is a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2021-05-31 English
Trading Halt 2 pages 161.5KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Genetic Technologies Limited regarding a trading halt requested under ASX Listing Rule 17.1. It states that the trading halt is pending the release of an announcement about the company's COVID-19 Serious Disease Risk Test. The document is short (1825 characters) and does not contain any financial data, report content, or detailed disclosures. It is an official notice related to trading status rather than a financial report or detailed announcement. Therefore, it fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-05-27 English
Change in substantial holding 5 pages 1.9MB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 604 Notice of change of interests of substantial holder' and references the Corporations Act 2001 Section 671B. It details changes in voting power and relevant interests of a substantial shareholder, The Bank of New York Mellon Corporation, in Genetic Technologies Limited. The content includes dates of changes, nature of changes, and voting power percentages. This type of filing is a notification of changes in significant share ownership levels, which aligns with the definition of Major Shareholding Notification (MRQ). The document is not an annual report, earnings release, or any other financial report but a regulatory notice about shareholding changes.
2021-05-25 English
Quarterly Activities Report & Appendix 4C 11 pages 1.2MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activities Report for the quarter ended 31 March 2021' and contains detailed operational and financial information for that quarter, including cash balances, cash flows, commercial agreements, regulatory updates, management appointments, and product development progress. It includes substantive financial data such as cash used in operations, receipts, expenses, and director payments. The document is comprehensive and covers a period shorter than a full fiscal year, consistent with an interim or quarterly report. It is not merely an announcement or a brief summary, nor is it a transcript, proxy, or governance document. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2021
2021-04-28 English
COVID- 19 Risk Test Approved for Commercial Release 2 pages 148.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX Market Announcement dated 26 April 2021 from Genetic Technologies Limited. It provides an update on the commercial release of the company's COVID-19 Risk Test in the US market, including regulatory submission details and expected launch timing. The content is an announcement about product commercialization progress and regulatory approvals, not a financial report, earnings release, or detailed investor presentation. The document is relatively short (4553 characters) and serves as a market update rather than a detailed report or filing. Therefore, it fits best into the category of Regulatory Filings (RNS), which is the fallback for general regulatory announcements and market updates that do not fit other specific categories.
2021-04-25 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.